- Home
- AFCG vs BWAY Comparison
AFCG vs BWAY Comparison
Compare AFCG & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFCG
- BWAY
- Stock Information
- Founded
- AFCG 2020
- BWAY 2003
- Country
- AFCG United States
- BWAY Israel
- Employees
- AFCG N/A
- BWAY N/A
- Industry
- AFCG Real Estate Investment Trusts
- BWAY Medical/Dental Instruments
- Sector
- AFCG Real Estate
- BWAY Health Care
- Exchange
- AFCG Nasdaq
- BWAY Nasdaq
- Market Cap
- AFCG 210.5M
- BWAY 177.2M
- IPO Year
- AFCG 2021
- BWAY 2019
- Fundamental
- Price
- AFCG $9.30
- BWAY $9.35
- Analyst Decision
- AFCG Buy
- BWAY Strong Buy
- Analyst Count
- AFCG 6
- BWAY 3
- Target Price
- AFCG $12.00
- BWAY $13.17
- AVG Volume (30 Days)
- AFCG 150.7K
- BWAY 67.0K
- Earning Date
- AFCG 11-13-2024
- BWAY 11-12-2024
- Dividend Yield
- AFCG 14.16%
- BWAY N/A
- EPS Growth
- AFCG N/A
- BWAY N/A
- EPS
- AFCG 0.40
- BWAY 0.04
- Revenue
- AFCG $43,164,939.00
- BWAY $38,631,000.00
- Revenue This Year
- AFCG N/A
- BWAY $378.91
- Revenue Next Year
- AFCG N/A
- BWAY $20.27
- P/E Ratio
- AFCG $23.28
- BWAY $117.76
- Revenue Growth
- AFCG N/A
- BWAY 34.19
- 52 Week Low
- AFCG $7.45
- BWAY $4.61
- 52 Week High
- AFCG $10.88
- BWAY $10.98
- Technical
- Relative Strength Index (RSI)
- AFCG 39.64
- BWAY 39.78
- Support Level
- AFCG $9.22
- BWAY $9.19
- Resistance Level
- AFCG $9.67
- BWAY $10.42
- Average True Range (ATR)
- AFCG 0.19
- BWAY 0.36
- MACD
- AFCG -0.02
- BWAY -0.10
- Stochastic Oscillator
- AFCG 8.45
- BWAY 8.33
About AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to state-law-compliant cannabis operators in the U.S. Through the management team's deep network and significant credit and cannabis expertise, AFC originates, structures and underwrites loans ranging from $10 million to over $100 million, typically secured by quality real estate assets, license value and cash flows.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.